Galapagos NV ADR (GLPG)vsBeiGene, Ltd. (ONC)
GLPG
Galapagos NV ADR
$30.64
+2.82%
HEALTHCARE · Cap: $2.26B
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 1762% more annual revenue ($5.34B vs $286.92M). ONC leads profitability with a 5.4% profit margin vs -1.5%. GLPG earns a higher WallStSmart Score of 47/100 (D+).
GLPG
Hold47
out of 100
Grade: D+
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GLPG.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 74.8% YoY
18.9% revenue growth
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
ROE of -16.7% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Operating margin of -58.6%
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : GLPG
The strongest argument for GLPG centers on Price/Book, EPS Growth, Revenue Growth. Revenue growth of 18.9% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : GLPG
The primary concerns for GLPG are Return on Equity, Free Cash Flow, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
GLPG profiles as a growth stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
GLPG scores higher overall (47/100 vs 42/100) and 18.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Galapagos NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?